SAN DIEGO, May 8, 2015 /PRNewswire/ -- A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive antiplatelet
medication after percutaneous coronary intervention (PCI), according to results of the TRIAGE study presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
The patient consented enrolment in the trial, and was randomized to one of the two treatment arms involving either three months or 12 months of Dual Antiplatelet
EfientA is an oral antiplatelet
agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited.
assessing compliance with treatment, stent thrombosis, very high-risk patients--all of which are situations that were not evaluated in the ARCTIC (Double Randomization of a Monitoring Adjusted Antiplatelet
Treatment versus a Common Antiplatelet
Treatment for DES Implantation, and Interruption versus Continuation of Double Antiplatelet
The goal of the current study was to perform a systematic review of the literature to determine if administering intravesical BCG in patients on oral anticoagulant or antiplatelet
medications affects the prognosis.
These results suggest that indole-3-carbinol can be a potent antithrombotic agent with antiplatelet
activity through the inhibition of GP IIb/IIIa receptor and thromboxane B2 formation.
For individuals taking antiplatelet
medications, platelet reactivity testing measures levels of platelet reactivity.
The anticipated reduction in cost is expected to keep the drug on its perch as the leading nonaspirin antiplatelet
agent, experts agree.
Also, we were first in the state of Arkansas to have access to some of the newest stents, cath lab devices, antiplatelet
drugs, and endografts.
A large clinical trial (n=1358) involving hospitalized patients admitted with an acute coronary syndrome placed patients into three groups: those who had never taken an oral antiplatelet
agent [nonusers] (n=930), those with a history of prior use (n=355) and those who had recently discontinued use (n=73).
This review included advice for patients with TAVI who present for non-cardiac surgery, stating that antiplatelet
drugs could be stopped and that full heparinisation was not needed in such cases.
Aspirin, ticlopidine and the combination of dipyridamole plus aspirin are all effective antiplatelet
agents for secondary stroke prevention.